Xeris Biopharma (NASDAQ:XERS) Insider Sells $124,169.15 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $7.45, for a total value of $124,169.15. Following the completion of the sale, the insider owned 1,243,174 shares of the company’s stock, valued at $9,261,646.30. The trade was a 1.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Beth Hecht also recently made the following trade(s):

• On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.43, for a total value of $123,835.81.
• On Monday, December 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.01, for a total value of $116,835.67.
• On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.40, for a total value of $123,335.80.

Xeris Biopharma Price Performance

XERS stock opened at $7.08 on Thursday. Xeris Biopharma Holdings, Inc. has a 1-year low of $3.44 and a 1-year high of $10.08. The business has a 50 day simple moving average of $7.28 and a two-hundred day simple moving average of $7.50. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -70.79 and a beta of 0.52.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to analysts’ expectations of $74.19 million. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Friday, January 9th. Zacks Research downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, Barclays began coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.08.

Hedge Funds Weigh In On Xeris Biopharma

Large investors have recently modified their holdings of the stock. AlphaQuest LLC bought a new stake in Xeris Biopharma in the third quarter worth $35,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Xeris Biopharma in the 3rd quarter worth about $68,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Xeris Biopharma by 913.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock worth $81,000 after purchasing an additional 15,678 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.